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Abstract
The development of tumor vasculature is thought to
occur through two complementary processes: sprout-
ing angiogenesis from preexisting blood vessels of
the host, and vasculogenesis, which involves the spon-
taneous development of vessels through specific re-
cruitment, differentiation, and vascular incorporation of
circulating endothelial cells (EC), endothelial progeni-
tor cells (EPC), or potentially bone marrow–derived
cells. Recent reports, however, have challenged the
belief that bone marrow–derived cells contribute to
tumor neovascularization, claiming an exclusive role
for sprouting angiogenesis in tumor blood vessel
development. In the present study, we explored the
recruitment behavior of bone marrow–derived lin–c-
kit+Sca-1+ stem cells to subcutaneously implanted
Lewis lung carcinoma in a syngeneic bone marrow
transplantation model. We observed that although
lin–c-kit+Sca-1+ and their derived cells demonstrate
significant recruitment to carcinomas in vivo, they do
not appear to functionally contribute to tumor neo-
vascularization. Furthermore, our results support the
hypothesis that new vessel formation in carcinomas
occurs primarily through endothelialization from adja-
cent and preexisting vasculature.
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Introduction
Vascularization is inherent to tumor growth, development,
and metastasis. Tumor vasculature develops through two
complementary processes: sprouting angiogenesis from
preexisting blood vessels of the host [1,2], and vasculo-
genesis, the spontaneous development of vessels through
specific recruitment behaviors of circulating endothelial cells
(EC), endothelial progenitor cells (EPC), or potentially bone
marrow–derived cells, followed by differentiation and vas-
cular incorporation [3–9]. Recent reports, however, have
challenged the belief that bone marrow–derived cells con-
tribute to tumor neovascularization, claiming an exclusive
role for sprouting angiogenesis in tumor blood vessel develop-
ment [10,11].
Specific subsets of the adult bone marrow appear to be
involved in neoangiogenic processes in a variety of physiologi-
cal and pathologic settings [3,12,1,13–18]. More specifically,
murine bone marrow–derived EPCs, bearing the phenotype
linc-kit+Sca-1+VE-cadherin+VEGFR2+, have been shown to
corecruit to tumors with linc-kit+Sca-1+Thy lo hematopoietic
stem cells (HSC) and hematopoietic progenitor cells (HPC),
especially of the VEGFR1+ myeloid phenotypic subset, and
participate in tumor neovascularization [6,19,20]. A role for
ex vivo expanded embryonic EPC in vasculogenesis has
also been explored in detail [21,22]. The dynamic mobilization
of these proangiogenic progenitor cells from the bone mar-
row compartment into the circulation involves a chemokine-
mediated and cytokine-mediated activation of proteases, in
combination with the upregulation of various adhesion mole-
cules [23]. Recent reports have indicated a role for bone mar-
row eNOS in the mobilization of these progenitor and stem
cells [24,25]. The recruitment of these recently mobilized cells
to sites of tissue injury or pathology also must require specific
adhesion molecules, chemokines, and associated molecules.
A recent study has indicated a role for selectins in the multi-
step recruitment and differentiation of embryonic EPC within
tumor microvasculature [21], and neuronal progenitor cell re-
cruitment has been demonstrated to be dependent on a com-
bination of a4-integrin and SDF-1a [26].
In the present study, we explored the recruitment behavior of
bone marrow–derived linc-kit+Sca-1+ stem cells to subcuta-
neously implanted Lewis lung carcinoma (LLC) in a syngeneic
bone marrow transplantation model. Although our data conclu-
sively demonstrate that linc-kit+Sca-1+ and their derived cells
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traffic to carcinomas in vivo, our results do not reveal a role for
these recruited cells in tumor neovascularization. In fact, our
results support the hypothesis that new vessel formation




RPMI 1640, DMEM, L-glutamine, penicillin–streptomycin,
sodium bicarbonate solution, Dulbecco’s PBS (DPBS)
(no Ca2+/Mg2+), DPBS+ (with Ca2+/Mg2+), and HBSS were
from Cambrex Bio Products (Walkersville, MD). Antibiotin
microbeads and lineage depletion Midi MACS kit were
obtained from Miltenyi Biotec (Auburn, CA). FCS was from
Cellgro (Herndon, VA). Additional molecular biology–grade
chemicals were from either Fisher Scientific (Suwanee, GA)
or Sigma Chemical Co. (St. Louis, MO).
Antibodies
Mouse Lineage Panel (biotinylated antibodies; CD3e,
CD11b, CD45R, Ly6G/C, and TER-119), purified rat anti-
mouse CD31 (clone MEC13.3, rat IgG2an), CD16/32 (Fc
gRIII/II, clone 2.4G2, rat IgG2bn), phycoerythrin (PE)–
conjugated rat antimouse Ly-6A/E (Sca-1, clone D7, rat
IgG2an), and allophycocyanin (APC)–conjugated rat anti-
mouse CD117 (c-kit, clone 2B8, rat IgG2bn) were obtained
from BD Pharmingen (San Jose, CA). Purified anti–mouse/
human smooth muscle actin (SMA) was obtained from Lab
Vision Corp. (Fremont, CA), Cy3 goat–antirat IgG (H+L)
and Texas Red anti–rabbit IgG (H+L) were obtained from
Caltag Laboratories (Burlingame, CA) and Vector Labora-
tories (Burlingame, CA), respectively. Streptavidin-PE was
from Miltenyi Biotec.
Mice
C57Bl/6 mice were purchased from Charles River Park
(Wilmington, MA). C57BL/6-Tg (ACTbEGFP)1Osb/J EGFP-
transgenic mice were obtained from Jackson Laboratories
(Bar Harbor, ME). All mice were maintained and bred in our
approved institutional pathogen and viral-free housing
facilities. Mice were used between 7 and 9 weeks of age
(20–25 g). For imaging experiments, animals were anesthe-
sized either through intraperitoneal injection with ketamine/
xylazine (80/12 mg/kg) or isofluorane anesthesia, and sac-
rificed by CO2 asphyxiation as approved by the panel on
euthanasia at the American Veterinary Association.
Cell Culture
LLC cells were a generous gift from Dr. Timothy Browder
(Children’s Hospital, Boston, MA). Cells were cultured in
DMEM supplemented with 10% FCS, L-glutamine, sodium
bicarbonate, and penicillin–streptomycin, grown to conflu-
ence and split biweekly in a 1:5 split ratio. For tumor
implantation studies, the cells were dissociated enzy-
matically, washed by centrifugation, and resuspended in
normal saline for injection.
Isolation of Bone Marrow–Derived Lineage Negative
Stem Cells (BMlin)
Murine bone marrow cells were recovered from the tibias
and femurs of C57Bl/6 mice by flushing with RPMI 1640,
disaggregated, and filtered through a 30-mm nylon filter.
Cells were then washed, resuspended to 1  108 cells/ml in
DPBS containing 1% heat-inactivated FCS, and incubated
for 5 minutes with anti–mouse CD16/CD32 (1 ml/106 cells)
on ice, followed by incubation with mouse lineage panel
antibodies (2 ml/106 cells) for 15 minutes on ice. The cells
were washed twice in DPBS containing 0.5% BSA and
20 mM EDTA, pH 7.2, and then selected with streptavidin
microbeads (2 ml/106 cells) for 15 minutes at 4jC, washed
twice, and separated magnetically in a lineage depletion
column to recover the unbound lineage-negative fraction.
Flow Cytometry
Whole bone marrow (wbm), BMlin, and lineage positive
cells (BMlin+) were separately incubated for 30 minutes on
ice with a biotinylated cocktail of antibodies directed against
lineage markers (lineage panel). In some instances, the
cells were also incubated in parallel with PE-Sca-1 Ab
and APC-c-kit Ab. The cells were washed twice in RPMI
1640 containing 5% FCS and incubated with streptavidin-
PE (dilution 1:11) for 5 to 7 minutes at 4jC for lineage
marker recognition. The cells were washed 3 and fixed
in 2% paraformaldehyde. Fluorescence of 10,000 cells per
sample was then determined in multiple channels on a
FACSCalibur flow cytometer (Becton Dickinson, Mountain
View, CA) and presented as quadrant plots and single
parameter histograms on a four-decade scale.
Biodistribution of 111Indium Oxine–Labeled BMlin Cells
in C57Bl/6 Mice Bearing Subcutaneous LLC Tumors
C57Bl/6 mice were implanted bilaterally with subcuta-
neous injections of 5  106 LLC in 100 ml of normal saline.
After 10 days, BMlin cells were isolated, resuspended to
2.5  106 /ml in RPMI 1640, and incubated with 0.5 mCi
of 111indium oxine (Amersham Health, Princeton, NJ) for
60 minutes at 37jC. Cells were then washed twice to remove
unbound reagent and tested for viability using trypan blue
exclusion. Labeling efficiency and sample radioactivity were
estimated in a gamma counter. Pools of 200,000 111indium-
labeled BMlin cells were then injected into six LLC tumor-
bearing C57Bl/6 mice through the tail vein. Twenty-four and
72 hours postinjection, three animals each were sacrificed,
their organs harvested, and radioactive counts were esti-
mated in a gamma counter. Radioactivity in each organ is
expressed as a fraction of the injected dose per organ.
Blood volume fractions for different organs were esti-
mated by combining experimental volume and density mea-
surements with blood and interstitial volume fraction data
based on a mathematical model [27]. Experimental radio-
activity measured in a small blood sample drawn from the
animal prior to sacrifice was then scaled up to account for
total blood radioactivity per organ. The percent injected
dose/organ could therefore be corrected for the vascular
contribution in that respective organ. In control experiments,
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similar labeling and injection procedures of BMlin+ cells
were performed.
Bone Marrow Repopulation Studies
Ten C57BL/6 WT mice were irradiated at 10.25 Gy
and, 1 day later, injected intravenously with a combination
of 4.5 105 BMlin+ carrier bone marrow cells recovered from
syngeneic wild-type C57Bl/6 mice, and 5  104 EGFP-
BMlin stem cells isolated from the wbm of EGFP-transgenic
mice to generate EGFP chimeras (WT mice carrying an
EGFP hematopoietic system, n = 3 for each time point).
On days 3 and 17 postinjection, these mice were subcuta-
neously implanted with LLC as described previously. Tumors
were also implanted bilaterally in WT nonirradiated C57BL/6
control mice (n = 2) and EGFP-transgenic mice (n = 3). On
days 10 to 14 following tumor implantation, imaging was
performed and the tumors were harvested for correlative
histologic analysis.
Imaging and Indirect Immunofluorescence Staining of
LLC Tumors
For epifluorescence imaging studies, both the chimeric
and WT control mice were anesthesized, and tumors were
exposed through fine incisions in the skin. The tumors, still
attached to the animal, were then inverted on a glass cover-
slip and imaged on an inverted Axiovert 100TV fluorescence
microscope (Carl Zeiss Imaging, Inc., Thornwood, NY) fitted
with a Cool Snap HQ camera (Roper Scientific, Tucson,
AZ). Images were acquired at 10 and 20 magnification
under both bright light and FITC channels for subsequent
image analysis. The animals were then sacrificed and
the tumors excised for indirect immunofluorescence stain-
ing. Based on previously published methods [28], excised
LLC solid tumors were fixed in 2% paraformaldehyde, equili-
brated in 18% sucrose, embedded in OCT, snap-frozen in
liquid N2, and serially sectioned in 7- to 10-mm sections.
Tissue sections were blocked with DPBS+ containing 1%
mouse serum for 30 minutes at 37jC and then incubated
for 45 minutes at 37jC with primary monoclonal antibody
(mAb) directed against mouse CD31 and SMA (20 mg/ml),
rinsed 3 in DPBS+, and detected with Cy3 or Texas
Red–conjugated secondary mAbs (1/100). Coverslips were
then washed and mounted using Vectashield (Vector Labo-
ratories). Fluorescence staining was visualized using a
Nikon Eclipse 80i upright microscope equipped for fluores-
cence and coupled to a Photometrics Cascade 512B
camera (Roper Scientific). Images were acquired with
10 and 20 objectives.
Results
BMlin Cells Are Recruited to Subcutaneously Implanted
LLC In Vivo
We magnetically depleted wbm isolated from adult
C57Bl/6 mice to recover pluripotent lineage negative (lin)
stem cells. As revealed in a histogram plot for lineage
marker recognition (Figure 1), the lin subset overlaps with
the negative isotype control, whereas the lineage positive
population (lin+) representing the differentiated components
of the wbm is highly positive for lineage marker expression.
The wbm primarily contains partially differentiated subma-
ture cells, as recognized by the lineage markers CD3e,
CD11b, CD45R, Ly6G/C, and TER-119, with a minor frac-
tion of immature pluripotent cells that are lineage negative.
As indicated in the lower panels, >95% of the recovered
lin stem cell population is positive for CD117 (c-kit, panel B)
and Sca-1 (panel C) expression. Taken together, our char-
acterization data reveal a highly enriched adult stem cell
population of the phenotype linc-kit+Sca-1+, which we
termed BMlin cells.
To explore the hypothesis that adult BMlin cells home
to implanted tumors in vivo, six adult C57Bl/6 mice bearing
10-day–old subcutaneous LLC tumors were injected intra-
venously with 111indium oxine–labeled stem cells and sac-
rificed 24 and 72 hours after stem cell injection. Radioactive
counts in harvested organs were expressed as a percentage
of the total injected dose. The radioactivity provides a direct
measure of the number of cells within each organ. Our bio-
distribution study (Figure 2) revealed that approximately
2% of the intravenously injected stem cells trafficked to
tumors within 24 hours postinjection (shaded bars) and
were retained in the tumor for at least 72 hours (open bars).
In addition to tumor homing, approximately 50% of the in-
jected dose was cleared by the liver, whereas <5% of the
injected stem cells was found in the kidneys, lungs, and fat.
The blood contained approximately 3% of the injected radio-
active dose, most likely due to labeled circulating cells; thus,
Figure 1. Characterization of bone marrow–derived lineage negative stem
cells. BMlin cells were depleted from wbm of C57Bl/6 mice as described in
Materials and Methods section. BMlin, BMlin+, and wbm populations were
stained for lineage markers and compared to an isotype control by flow
cytometry (A). BMlin cells were stained also for the presence of c-kit (B) and
Sca-1 (C). Isolated BMlin cells were >95% pure and >95% positive for both
Sca-1 and c-kit as indicated by the fluorescence intensities of mAbs directed
against lineage markers (lineage) and Sca-1 and c-kit.
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the percent injected dose per organ was corrected for the
predicted radioactive contribution of the blood pool in that
organ. Our data suggest, therefore, that the majority of in-
jected BMlin cells were ‘‘noncirculating’’ organ or tumor re-
sident cells at the times studied.
BMlin Cells and Their Progeny Are Recruited to
Subcutaneous LLC In Vivo, But Do Not Aid
in Vasculogenesis
The biodistribution studies indicated a level of BMlin cell
recruitment to LLC tumors in the initial 72 hours following
adoptive transfer of labeled cells; however, these studies
did not provide specific information on the intratumoral dis-
tribution of the recruited cells. To address this question, we
generated EGFP/C57Bl/6 chimeric animals expressing
EGFP in their hematopoietic system and used these ani-
mals as tumor hosts. At 14 days following tumor injection,
the live tumors were imaged to determine the contribution of
hematopoietic cells to the vasculature of the subcutaneous
tumors (Figure 3). Real-time epifluorescence imaging of
exteriorized subcutaneous tumors in EGFP-chimeric mice
demonstrated recruitment of BMlin cells and their progeny
to LLC in vivo. Although a majority of the tumor-recruited
cells appeared to reside in the extravascular tissue, we did
observe a few firmly arrested EGFP cells within the tumor
vasculature (Figure 3C, inset); however, none of the fluores-
cent cells was observed to contribute directly to vessel
structure. A similar recruitment behavior was observed for
tumors implanted either within 3 days of bone marrow
transplantation when only EGFP-BMlin cells were present
in the circulation, or over 2 weeks following bone marrow
repopulation when mature progeny cells were also present,
suggesting that both BMlin stem cells and progeny cells are
recruited to LLC tumors. As expected, no EGFP signal was
detected in the vasculature or in the surrounding tumor tissue
in WT control mice (Figure 3A).
To further interrogate the contribution of BMlin cells, or
their progeny, to tumor composition, we performed correla-
tive histology of the same tumors. Following epifluorescence
imaging, tumors fromWT control mice and EGFP chimeras
were harvested, sectioned, and stained for CD31 and SMA
(Figure 4) to identify endothelial and smooth muscle cells of
the tumor vasculature. Dual-channel images of tumor sec-
tions from EGFP-chimeric mice confirmed the presence of
recruited EGFP cells (green) within tumor tissue (28 cells/
mm2), but recruited cells did not coregister with staining
Figure 2. BMlin stem cells are recruited to subcutaneously implanted LLCs
in vivo. 111In oxine– labeled BMlin cells were injected intravenously into LLC
tumor-bearing C57Bl/6 mice and sacrificed either at 24 hours (filled bars) or
72 hours (open bars) following administration. Radioactive counts for each
organ were determined in a gamma counter and expressed as a percentage
of the injected dose per organ. Recruitment of approximately 2% of the in-
jected dose was observed in these tumors at the times studied (n = 3 for
each time point).
Figure 3. BMlin cells and their progeny are recruited to LLCs through the
tumor vasculature. We performed live epifluorescence imaging of 14-day–old
exteriorized tumors implanted in either WT (n = 2; panel A) or EGFP-chimeric
mice (n = 3; panels B and C) 14 days following bone marrow transplantation.
Arrested EGFP+ cells were observed to traffic from within the vasculature
(panel C, inset) to the extravascular tumor tissue in EGFP-chimeric mice
(B and C), but no fluorescent cells were detected under similar conditions for
tumors implanted in WT mice. Similar results were observed at 3 days post
bone marrow transplantation.
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for components of the tumor vasculature (red), indicated by
the lack of EGFP correlation with CD31 (Figure 4, panel C)
or SMA (panel D). In statistical analysis of multiple tissue
sections, a maximum of 6 cells/mm2 was observed to costain
with CD31 and EGFP, less than 20% of the total EGFP cells
per square millimeter, and no cells costained with SMA. In
contrast, when LLC were injected into transgenic ubiqui-
tously EGFP-expressing animals, indirect immunofluores-
cence staining revealed that all of the blood vessels (red)
in these tumors, as detected by CD31 (panel E) and SMA
(panel F), were EGFP+ (green). As expected, no EGFP cells
were detected in tumors from WT control mice (panels A
and B). In entirety, these data do not support a role for bone
marrow–derived stem cells in the vascularization of LLCs,
but in fact indicate that vessel growth occurs through the
participation of adjacent preexisting vasculature.
Discussion
A number of recent reports have suggested a role for bone
marrow–derived cells in tumor vasculogenesis. The relevant
subsets of the adult wbm that appear to functionally partici-
pate in neovascularization are the angioblast-like EPC
and the facilitative HSC or HPC cells [29,3,4,6,7,30,8]. How-
ever, the degree of recruitment of these cells has not been
effectively quantitated, the mechanisms of recruitment are
not understood, and a specific role for these recruited cells in
tumor vessel growth and development has not been fully
elucidated. Thus, we employed a primitive linc-kit+Sca-1+
stem cell population (BMlin) that is phenotypically inclusive
of these specific neoangiogenic subsets, in a syngeneic
model of stem cell recruitment to tumors, to both quantify
BMlin recruitment and address the question of BMlin
function in tumor neovascularization.
From our biodistribution data (Figure 2), we have deter-
mined quantitatively that BMlin cells are recruited to subcu-
taneously implanted LLCs, and that these cells are present
in the tissue and not simply circulating through the tumor
vasculature. However, the fraction of injected cells that are
recruited to the tumor environment is far lower than that
observed for recruitment of human CD34+ cells to the bone
marrow in immunodeficient mice [31], for recruitment of
antigen-specific CD8+ T cells to antigen-expressing tumors
[32], or for the recruitment of neuronal progenitors to the
same LLCs in vivo [26]. These data suggest that BMlin cells
exhibit a limited potential for the contribution to actively and
aggressively growing tumors. However, it could be argued
that very few long-term repopulating BMlin cells are actually
required to initiate these events, just as very few true HSCare
required to repopulate the bone marrow. It is possible that a
few BMlin cells are recruited, and then go on to expand and
differentiate in the tumor environment. The biodistribution
data alone are not capable of determining the degree of cell
proliferation, and thus we developed the bonemarrowEGFP-
chimeric animals to address these questions specifically.
Fluorescence imaging of live LLCs implanted into EGFP-
chimeric mice at two different time points following bone
marrow transplantation, coupled with indirect immunofluo-
rescence staining of the harvested tumor sections, revealed
a number of resident EGFP cells within the tumor mass.
However, other than the presence of a few arrested EGFP
cells within the tumor circulation, our data do not support a
role for the recruited hematopoietic cells in tumor neovascu-
larization, evident by the lack of coregistration of CD31/SMA
staining and EGFP expression in tumors carried by EGFP-
chimeric animals. However, in EGFP-transgenic mice that
express EGFP ubiquitously, all tumor vessels identified
exhibited both EGFP expression and staining for CD31 and
SMA. Together, these data support the hypothesis that
tumor vessel growth in LLCs occurs through sprouting of
the existing host circulation—not through spontaneous vas-
culogenesis of circulating progenitor cells. Our observations
are supported by a recent elegant study that examined the
recruitment of Tie2-expressing mononuclear EPC to tumors
[10]. The authors observed Tie2-expressing cells in the
tumor mass and in close proximity to tumor vessels after
long-term growth (12 weeks) of recipient tumors, but did
not observe any contribution of these cells to the tumor
vasculature directly.
Figure 4. Tumor neovascularization in LLC is not mediated by vasculo-
genesis due to recruited hematopoietic cells. LLC tumors implanted in either
WT mice (panels A and B), EGFP-chimeric mice (C and D, inset: magnified
view of individual vessel), or EGFP-transgenic mice (E–G) were stained for
CD31 and SMA. EGFP fluorescence images (green) were overlaid on
fluorescence images of CD31 or SMA (red) to yield dual-channel images
at 10 and 20 magnification. No fluorescent cells were present in tumor
sections from WT animals. In contrast, EGFP-expressing cells were detected
in sections from EGFP-chimeric (chimeric; panels C and D) or EGFP-
transgenic mice (transgenic; panels E–G); however, only in the EGFP-
transgenic animals did the green fluorescence due to EGFP coregister with
either CD31 or SMA staining (E and F). The triple overlay of EGFP (green),
CD31 (red), and SMA (blue) (panel G) confirms the presence of EGFP in the
tumor endothelial and smooth muscle cells of EGFP-transgenic animals.
Scale bars on leftmost panels represent the scale on all panels in that res-
pective row.
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Although the present study was supported by recent
reports, there remains a significant controversy as to the
functional incorporation of hematopoietic cells in sites of
neovascularization, and how these conflicting reports may
be reconciled. There are specific and significant differences
in the tumor models exploited in these studies, which may go
some way toward explaining the differing observations
reported. Probably of most critical consequence is the type
of tumor used. Recent reports that demonstrated vascular
incorporation of EPC or other hematopoietic cells have
used either colon cancer cell lines [3] or tumors of neuronal
origin [4,21], which may represent a significant departure
from the LLC model employed in the current study. Even
more interesting are the reports indicating that tumor
growth is significantly retarded in the absence of a normally
functioning hematopoietic system, or when hematopoietic
subsets have been modified to limit their recruitment or
potential [4,6,9]. At initial interpretation, these data would
suggest that hematopoietic cells do contribute directly to
tumor vessel growth; however, recently, it has been hypoth-
esized that HSC or HPC represent a ‘‘helper’’ subset that
directs and stabilizes neovascularization within tumors, but
does not itself participate in vasculogenesis [19]. This hy-
pothesis is supported not only by the retarded growth of
tumors in the absence of functional HSC, but also by the
location of these cells, in close proximity to new vessels in
the developing tumor mass.
In conclusion, we have demonstrated that whereas long-
term repopulating stem cells are recruited in low levels to
subcutaneously implanted LLCs in syngeneic animals, nei-
ther them nor their progeny contributes directly to vasculo-
genesis in this model. Together, these data would suggest
caution in interpretation of the role of these cells in any site
of spontaneous or induced neovascularization.
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